Hoth Therapeutics Aktie [WKN DE: A2PTV0 / ISIN: US44148G1058]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Hoth Therapeutics Inc Registered Shs

09.11.22		Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
31.10.22		Hoth Reports Positive Biolexa Phase 1b Trial Results In Mild To Moderate Atopic Dermatitis; Stock Up (RTTNews)
31.10.22		HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS (PR Newswire)
24.10.22		Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 (PR Newswire)
20.09.22		Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke (RTTNews)
20.09.22		Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke (PR Newswire)
06.09.22		Hoth: Treatment With HT-004 Significantly Reduces Lung Inflammation In Asthma, Allergy Mouse Model (RTTNews)
06.09.22		Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders (PR Newswire)
12.08.22		Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference (PR Newswire)
12.07.22		Hoth Says HT-ALZ Therapeutic Shows Cognitive Improvements In Alzheimer's Disease Mouse Model (RTTNews)
12.07.22		Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model (PR Newswire)
29.06.22		Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (PR Newswire)
21.06.22		Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis (PR Newswire)
15.06.22		Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022 (PR Newswire)
09.06.22		Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ (PR Newswire)
03.05.22		Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort (PR Newswire)
19.04.22		Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury (PR Newswire)
14.04.22		Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire)
12.04.22		Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference (PR Newswire)
12.04.22		Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market (PR Newswire)
11.04.22		Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
11.04.22		Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer Cells (PR Newswire)
01.04.22		Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention (PR Newswire)
22.03.22		Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance (PR Newswire)
11.03.22		Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis (PR Newswire)
09.02.22		Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients (PR Newswire)
07.02.22		Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference (PR Newswire)
31.01.22		Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board (PR Newswire)
04.01.22		Hoth Therapeutics: HT-ALZ Reduces Circulating Brain Aß In Alzheimer's Disease Mouse Model (RTTNews)
04.01.22		Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease (PR Newswire)
21.12.21		Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis (PR Newswire)
08.12.21		Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics (PR Newswire)
30.11.21		Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way (PR Newswire)
16.11.21		Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT (PR Newswire)
08.11.21		Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic (PR Newswire)
19.10.21		Hoth Therapeutics Extends Partnership Agreement with REPROCELL (PR Newswire)
12.10.21		Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients (PR Newswire)
21.09.21		Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial (PR Newswire)
08.09.21		Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa (PR Newswire)
11.08.21		Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy (PR Newswire)
13.07.21		Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne (PR Newswire)
28.06.21		Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis (PR Newswire)
07.06.21		Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ (PR Newswire)
23.03.21		Hoth: Extremely Positive In Vitro Data Supports HT-002's Antiviral Activity Against SARS-CoV-2 (RTTNews)
13.01.21		FDA Grants Hoth Pre-IND Meeting On Proposed Drug Development Plan For HT-001 Treatment (RTTNews)
06.01.21		MRKR Soars As FDA Lifts Hold On MT-401, RYTM Sells Priority Review Voucher, MLND Dumps MLE-301 (RTTNews)
31.12.20		Stock Alert: Hoth Therapeutics Surges 50% (RTTNews)
31.12.20		Hoth Therapeutics Inks Production Deal With Tergus Pharma For HT-001 GLP And GMP Materials (RTTNews)
27.08.20		Pre-market Movers In Healthcare Sector: EYPT, CLVS, ABT, VBIV, LPCN... (RTTNews)
19.05.20		Stock Alert: Hoth Therapeutics Rises 15% On Full Licensing Rights For BioLexa (RTTNews)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple Kurs Prognose: 10 US-Dollar bereits in wenigen Wochen?

NVIDIA vor Zahlen: Bank of America sieht Mega-Potenzial

Bitcoin & Co.: "Dr. Doom" Roubini prognostiziert Krypto-Blase und warnt Anleger

US-Zölle im Fokus: US-Börsen schließen schwach -- ATX schließt tiefer -- DAX letztlich in Rot -- Märkte in Fernost gehen tiefer aus dem Handel

Mercedes-Benz-Aktie fällt: Gewinneinbruch und niedrigere Dividende

Ceres Power-Aktie mit heftigem Kursrutsch: Bosch kündigt Partnerschaft auf

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.02.2025 11:42
Kaufwert:	EUR
	Hinzufügen Speichern